These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 4052923)

  • 1. Comparison of cytotoxicity of single dose and infusion of alkylating agents.
    Valeriote F; Vietti T
    Cancer Drug Deliv; 1985; 2(1):11-8. PubMed ID: 4052923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of drug transport in resistance to nitrogen mustard and other alkylating agents in L518Y lymphoblsts.
    Goldenberg GJ
    Cancer Res; 1975 Jul; 35(7):1687-92. PubMed ID: 1055634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
    Griswold DP; Trader MW; Frei E; Peters WP; Wolpert MK; Laster WR
    Cancer Res; 1987 May; 47(9):2323-7. PubMed ID: 3567926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
    Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
    Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of cytotoxic action of iphosphamide and cyclophosphamide.
    Phelan ET; Vietti TJ; Valeriote FA; Coulter D
    Anticancer Res; 1981; 1(3):149-54. PubMed ID: 7342853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of tetraacetylglucosamine mustard.
    Wampler GL; Nassiri SK; Hsiao YY; Bardos TJ; Regelson W
    Cancer Res; 1975 Aug; 35(8):1903-6. PubMed ID: 1149014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of current alkylating agents with a homo-aza-steroidal ester for antineoplastic activity.
    Catsoulacos P; Papageorgiou A; Margarity E; Mourelatos D; Mioglou E
    Oncology; 1994; 51(1):74-8. PubMed ID: 8265107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of scheduling on two-drug combinations of alkylating agents in vivo.
    Teicher BA; Holden SA; Jones SM; Eder JP; Herman TS
    Cancer Chemother Pharmacol; 1989; 25(3):161-6. PubMed ID: 2513139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular pharmacokinetics of the phenylalanine mustards.
    Vistica DT
    Pharmacol Ther; 1983; 22(3):379-406. PubMed ID: 6361804
    [No Abstract]   [Full Text] [Related]  

  • 10. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
    Tanaka J; Teicher BA; Herman TS; Holden SA; Dezube B; Frei E
    Int J Cancer; 1991 Jun; 48(4):631-7. PubMed ID: 2045206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-,dihydrochloride. III. Biochemical and therapeutic effects in L1210 leukemias sensitive and resistant to alkylating agents: comparison with melphalan, cyclophosphamide, and BCNU.
    Schabel FM; Trader MW; Laster WR; Shaddix SC; Brockman RW
    Cancer Treat Rep; 1976 Sep; 60(9):1325-33. PubMed ID: 1016968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ablation of murine jejunal crypts by alkylating agents.
    Moore JV
    Br J Cancer; 1979 Feb; 39(2):175-81. PubMed ID: 219878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of resistance and therapeutic synergism among alkylating agents.
    Schabel FM; Trader MW; Laster WR; Wheeler GP; Witt MH
    Antibiot Chemother (1971); 1978; 23():200-15. PubMed ID: 348078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Possibilities of decreasing the toxicity of lethal doses of radiominetics by the use of radioprotectors].
    Pantev T; Petkova S
    Eksp Med Morfol; 1978; 17(1):14-8. PubMed ID: 639742
    [No Abstract]   [Full Text] [Related]  

  • 15. Combination of the new minor groove alkylator tallimustine and melphalan.
    Tagliabue G; Filippini C; Ubezio P; D'Incalci M
    Eur J Cancer; 1997 Feb; 33(2):284-7. PubMed ID: 9135501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
    Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transport and cytotoxicity of amino acid nitrogen mustards: implications for the design of more selective antitumor agents.
    Vistica DT; Ahmad S; Fuller R; Hill J
    Fed Proc; 1986 Sep; 45(10):2447-2450. PubMed ID: 3743787
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
    Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
    Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elimination of EL-4 and L1210 murine tumors by 1,3-bis (2-chloroethyl)-1-nitrosourea requires an intact immune response.
    Steele TA; Cox DC
    Proc Soc Exp Biol Med; 1996 May; 212(1):63-8. PubMed ID: 8618953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic lethal action of alkylating agents and sodium pentobarbital in the mouse.
    Munson AE; Rose WC; Bradley SG
    Pharmacology; 1974; 11(4):231-40. PubMed ID: 4218647
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.